Type 2 diabetes mellitus. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: The patients in the intervention group will receive 1200 mg daily of alpha-lipoic acid supplements in the form of two 600 mg capsules and they will be asked to take
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Willingness to cooperate Age between 40-60 years old Body mass index (BMI) between 18.5 to 29.9 At least 2 years of diagnosed type 2 diabetes Controlled diabetes (HbA1C < 7%)
Exclusion criteria
Exclusion criteria: Taking insulin History of angina, myocardial infarction, and stroke, as well as other chronic diseases including liver disease, gastrointestinal disease, kidney disease, malignant disease, thyroid disease and other chronic and infectious diseases in the past year Tobacco and alcohol consumption in the last three months Changes in treatment protocols in the last three months Taking any medicine other than metformin, glibenclamide, statin drugs, ACEI, ARB and doses less than 80 mg aspirin Regular use of herbal Supplements containing antioxidants and omega-3 in the last three months (at least once a week) Pregnancy and lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lipoprotein-associated phospholipase A2 (Lp-PLA2). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;Lipoprotein-associated phospholipase A2 distribution among lipoproteins. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;ICAM-1. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;VCAM-1. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;TNF-a. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;Interleukin 6. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;8-Isoprostane. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;OX-LDL. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;Apolipoprotein A1. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay. | — |
Secondary
| Measure | Time frame |
|---|---|
| Glucose. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Photometric assay.;Insuline. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA assay.;Total cholesterol. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: enzymatic assay.;HDL Cholesterol. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: enzymatic assay.;LDL Cholesterol. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Friedewald formula.;Triglyceride. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: enzymatic assay. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Saeed Hosseini
Tehran University of Medical Sciences
Outcome results
None listed